Comparison of hypericum extract WS® 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: Results from a randomized multicenter study

Pharmacopsychiatry

Volumn 39, Issue 6, 2006, Pages 213-219

  Anghelescu, I G ^a   Kohnen, R ^b   Szegedi, A ^a   Klement, Stephan ^c   Kieser, M ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b IMEREM   (Germany)

^c DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERICUM EXTRACT; PAROXETINE; WS 5570;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; OUTPATIENT CARE; PHASE 3 CLINICAL TRIAL; PHOTOALLERGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERICUM; MALE; MIDDLE AGED; PAROXETINE; PLANT EXTRACTS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; TREATMENT OUTCOME;

EID: 33751260652     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-951388     Document Type: Article

References (50)

1. American Psychiatric Association. DSM - Diagnostic and Statistical Manual of Mental Disorders. [electronic mail system] 2000
2. Baldwin DS, Hawley CJ, Mellors K, CN104-070 Study Group. A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. J Psychopharmacol 2001; 15: 161-165
3. Beck AT, Steer RA. Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol 1984; 40: 1365-1367
4. Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev 2001; 7: 25-47
5. Bump GM, Mulsant BH, Pollock BG, Mazumdar S, Begley AE, Dew MA, Reynolds CF3. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety 2001; 13: 38-44
6. Chatterjee SS, Nöldner M, Koch E, Erdelmeier CAJ. Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 1998; 31 (Suppl 1): 7-15
7. Dunner DL, Kumar R. Paroxetine: a review of clinical experience. Pharmacopsychiatry 1998; 31: 89-101
8. Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998; 54: 589-594
9. Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 2005; 38: 78-86
10. Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 2006; 39: 66-75
11. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296
12. Harrer G, Hübner WD, Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. J Geriatr Psychiatry Neurol 1994; 7: S24-S28
13. Harrer G, Schmidt U, Kuhn U, Biller A. quivalenzvergleich Johanniskraut LoHyp-57 versus Fluoxetin. Arzneimittelforschung 1998; 49: 3-10
14. Hindmarch I. The behavioural toxicity of antidepressants: effects on cognition and sexual function. Int Clin Psychopharmacol 1998; 13: S5-S8
15. Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff J, Endicott J, Froom J, Goldstein M, Gorman JM et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997; 277: 330-340
16. Kasper S, Anghelescu IG, Szegedi A, Dienel A, Kieser M. Superior efficacy of St. John's Wort extract WS®5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial. BMC Medicine 2006; 4: 14 , doi:10.1186/1741-7015-4-14
17. Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials. Psychopharmacology 2002; 164: 301-308
18. Kasper S, Dienel A, Kieser M. Hypericum extract WS 5570 has a beneficial effect in continuation treatment of recurrent depression. Pharmacopsychiatry 2005; 38: 236, Ref Type: Abstract
19. Kasper S, Zapotoczky HG, Stuppäck C, König P, Wuschitz A. Diagnostik und Therapie der Depression - Konsensus statement. Neuropsychiatrie 1997; 11: 59-67
20. Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998; 44: 348-360
21. Keller MB, Hanks DL Anxiety symptom relief in depression treatment outcomes. J Clin Psychiatry 1995; 56 (Suppl 6): 22-29
22. Kim HL, Streltzer J, Goebert D. St. John's wort for depression: a metaanalysis of well-defined clinical trials. J Nerv Ment Dis 1999; 187: 532-539
23. Kupfer DJ. Lessons to be learned from long-term treatment of affective disorders: potential utility in panic disorder. J Clin Psychiatry 1991; 52 (Suppl): 12-16
24. Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger AG, Thase ME, McEachran AB, Grochochinski VJ. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49: 769-773
25. Laakmann G, Schüle C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998; 31 (Suppl 1): 54-59
26. Lauritzen L, Odgaard K, Clemmesen L, Lunde M, Ohrstrom J, Black C, Bech P. Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiatr Scand 1996; 94: 241-251
27. Lecrubier Y. Is depression under-recognised and undertreated? Int Clin Psychopharmacol 1998; 13 (Suppl 5): S3-S6
28. Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 2002; 159: 1361-1369
29. Linde K, Berner M, Egger M, Mulrow CD. St John's wort for depression: meta-analysis of randomised controlled trials. Br J Psychiatry 2005; 186: 99-107
30. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998; 55: 1128-1132
31. Montgomery SA. Long-term treatment of depression. Br J Psychiatry Suppl 1994; 31-36
32. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
33. Montgomery SA, Kasper S. Depression: a long-term illness and its treatment. Int Clin Psychopharmacol 1998; 13 (Suppl 6): S23-S26
34. Müller WE, Singer A, Wonnemann M. Hyperforin - antidepressant activity by a novel mechanism of action. Pharmacopsychiatry 2001; 34 (Suppl 1): S98-S102
35. National Institute of Mental Health CGI: Clinical Global Impressions. Guy, W. and Bonato, R. R. Manual for the ECDEU Assessment Battery 2nd rev., 12.1-12.6. 1976. Chevy Chase, MD. Ref Type: Serial (Book, Monograph)
36. Philipp M, Kohnen R, Hiller K-O. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ 1999; 319: 1534-1539
37. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995; 56 (Suppl 6): 12-21
38. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986; 143: 18-23
39. Settle EC Jr. Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Clin Psychiatry 1998; 59 (Suppl 16): 25-30
40. Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ 2005; 330: 503-506
41. Traynor K. Severe depression does not respond to St. John's wort, study says. Am J Health Syst Pharm 2001; 58: 954-956
42. Volz H-P. Controlled clinical trials of hypericum extracts in depressed patients - on overview. Pharmacopsychiatry 1997; 30 (Suppl 2): 72-76
43. Vorbach EU, Arnoldt KH, Hübner WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 30: 81-85.
44. Pharmacopsychiatry 1997; 30 (Suppl 2): 81-85
45. Vorbach EU, Hübner WD, Arnoldt KH. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients. J Geriatr Psychiatry Neurol 1994; 7 (Suppl 1): S19-S23
46. Welzel D, Kohnen R, Krüger HP, Vollrath M, Drechsler S. Farbskalen zur Messung von Befindlichkeit und Lebensqualität. In: Möller HJ, Engel RR, Hoff P, editors. Befunderhebung in der Psychiatrie: Lebensqualität, Negativsymptomatik und andere aktuelle Entwicklungen. Berlin: Springer, 1996; 133-152
47. Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. Pharmacopsychiatry 1997; 30 (Suppl 2): 77-80
48. Wheatley D. Hypericum extract - potential in the treatment of depression. CNS Drugs 1998; 9: 431-440
49. Williams JW Jr, Mulrow CD, Chiquette E, Hitchcock P, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann lnt Med 2000; 132: 743-756
50. Winkler D, Tauscher J, Kasper S. Maintenance treatment in depression: the role of pharmacological and psychological treatment. Curr Opin Psych 2002; 15: 63-68